Jeremy Hunt's heartbreak after brother's death from rare cancer: How Chancellor always had hope 'lovely' Charlie, 53, would survive sarcoma battle
Charlie Hunt, died in August aged just 53, three years after he was diagnosed with spindle cell sarcoma - an ultra-rare cancer affecting fewer than one in a million people. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2024 Category: Consumer Health News Source Type: news

BAMF Health to partner with Corewell Health
BAMF Health and Corewell Health Haworth Innovative Therapeutics Clinic plan to collaborate on a clinical trial to test targeted radiation therapy for cancer patients. The phase I trial is sponsored by Y-mAbs Therapeutics and will include both adolescent and adult patients with recurrent or resistant small-cell lung cancer, sarcoma, and malignant melanoma. Trial participants will receive tumor-targeting treatment with an antibody that binds to a protein called GD-2 on the surface of the cancer cells, then a radioisotope infusion that binds to the antibody and delivers the radiation to cancer cells, BAMF Health said. (Sourc...
Source: AuntMinnie.com Headlines - March 4, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment
Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective new treatment options for KSHV-associated cancers, including Kaposi's sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease. (Source: World Pharma News)
Source: World Pharma News - March 1, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Miami Cancer Institute to host second Precision Oncology Symposium to advance cancer treatment
Miami Cancer Institute, part of Baptist Health South Florida, will host its second annual Precision Oncology Symposium from April 19-20, according to the symposium organizers. This one-and-a-half-day symposium, to be held in Miami, has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors — including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas, and brain… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 19, 2024 Category: Biotechnology Authors: Baptist Health Source Type: news

Immunotherapy Before Sarcoma Surgery Improves Outcomes
Immunotherapy can improve outcomes in patients undergoing surgery for soft-tissue sarcomaImmunotherapy and radiation therapy prior to surgery led to 90% of patients having nearly all cancer cleared from their bodiesOverall five-year survival rates... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 15, 2024 Category: General Medicine Source Type: news

Can new image processing methods deliver reproducible radiomics?
In conclusion, we standardized eight types of convolutional filters for radiomics to ensure that the enhanced clinical insights that can be gained through their use can be validated and reproduced,” the authors wrote. “Going forward, developers should ensure compliance of their software with the proposed reference standards, and users are encouraged to use compliant software.” The group has also posted a web-based tool to assist in checking compliance with these reference standards. In the next phase of their work, the researchers are now working on standardizing image processing systems commonly used in deep-learn...
Source: AuntMinnie.com Headlines - February 7, 2024 Category: Radiology Authors: Erik L. Ridley Tags: Image Processing Source Type: news

News at a glance: ‘Lobster eye’ space telescope, psychiatrists’ conflicts, and elusive common sense
ASTRONOMY ‘Lobster eye’ in space promises new look at x-rays China last week launched an x-ray observatory with an unusual telescope inspired by the structure of lobster eyes to gather new data on gamma ray bursts, supernovae, and stars being swallowed by black holes. The Einstein Probe (illustration above)—a joint project of the Chinese Academy of Sciences, the European Space Agency, and the Max Planck Institute for Extraterrestrial Physics—will also capture x-rays from violent events that generate gravitational waves, such as two neutron stars colliding. The telescope features a survey inst...
Source: ScienceNOW - January 18, 2024 Category: Science Source Type: news

European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients,  nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Investor Update - January 16, 2024 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients,  nurses and physicians1-5Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possibleBasel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq ® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer...
Source: Roche Media News - January 16, 2024 Category: Pharmaceuticals Source Type: news

Great-grandad celebrating being cancer-free with 60 mile fundraising trek
EXCLUSIVE: Ralph White had surgery for a prostate sarcoma in 2012 then a bowel tumour led to a stay in Manchester's Christie Hospital in 2021 (Source: Daily Express - Health)
Source: Daily Express - Health - January 3, 2024 Category: Consumer Health News Source Type: news

Fluorescent green dye helps surgeons reduce complications after surgery for people with soft tissue sarcoma
A team of researchers at Mayo Clinic has discovered that using fluorescent green dye combined with imaging during surgery for soft tissue sarcoma can help surgeons determine what tissue may be at risk of poor healing. This information allows surgeons to change the wound closure to reduce the risk of complications as the patient heals. Soft tissue sarcoma forms in tissues that connect, support and surround other body structures, including muscle, fat, blood vessels, nerves, tendons… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 24, 2023 Category: Databases & Libraries Source Type: news

FDA Approves First Therapy for Progressive Desmoid Tumors
(MedPage Today) -- The FDA approved the first treatment for adults with progressive desmoid tumors, a rare type of benign soft-tissue sarcoma. The approval of oral nirogacestat (Ogsiveo) stipulates use in patients with progressive tumors that... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 28, 2023 Category: American Health Source Type: news

FDA approves first therapy for rare type of non-cancerous tumors
The U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. (Source: World Pharma News)
Source: World Pharma News - November 28, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors
The FDA approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Nirogacestat is a new molecular entity and the first drug to be approved for the treatment of patients with desmoid tumors, a subtype of soft tissue sarcomas. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 27, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news